GlassScriptPhysician profile
April Winkler
NPI 1104273861
$2,289.31
in general payments reported to CMS, 2019-2025
31 companies · $778 in 2025
The $778 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $524 · 2023: $354 · 2024: $382 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.26 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $375.19 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $208.86 | 2021-2025 | Zepbound, Jardiance, Emgality |
| Amgen INC. | $107.50 | 2022-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $100.97 | 2021-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.04 | 2025 | Caplyta |
| Novo Nordisk INC | $64.00 | 2021-2024 | Rybelsus, Ozempic |
| Vertex Pharmaceuticals Incorporated | $52.08 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $49.93 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $45.39 | 2022 | |
| Sunovion Pharmaceuticals INC. | $37.60 | 2022 | |
| Dexcom, INC. | $36.78 | 2022 | |
| Mylan Specialty L.P. | $34.37 | 2023 | Yupelri |
| Lundbeck LLC | $33.30 | 2023 | Rexulti |
| Amarin Pharma, INC. | $33.27 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.37 | 2022 | |
| Collegium Pharmaceutical, INC. | $31.18 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.78 | 2021-2022 | |
| Pfizer INC. | $28.27 | 2025 | |
| Merck Sharp & Dohme LLC | $28.02 | 2022-2025 | Gardasil 9, Capvaxive |
| Radius Health, INC. | $22.19 | 2025 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $19.24 | 2021 | |
| Abbott Laboratories | $19.14 | 2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $19.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.20 | 2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $15.62 | 2025 | Shingrix, Arexvy, Bexsero |
| Novartis Pharmaceuticals Corporation | $15.44 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2022 | |
| Verona Pharma, INC. | $13.91 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $13.85 | 2024 | Cologuard Collection Kit |
| Corium, LLC | $12.35 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Winkler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.